In the first head-to-head test, Eli Lilly’s Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk’s Wegovy.
People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday.
That translated into an average 50-pound loss for people who took Zepbound, while Wegovy users lost 33 pounds.
PS: Zepbound and Mounjaro are the same drug with different brand names, as are Ozempic and Wegovy.
CNMRI: Neurology, Sleep Medicine, MRI 